药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
D-Levofloxacin
The serum concentration of Choline salicylate can be increased when it is combined with D-Levofloxacin.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Solriamfetol
The serum concentration of Solriamfetol can be increased when it is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Varicella Zoster Vaccine (Live/attenuated)
The risk or severity of adverse effects can be increased when Choline salicylate is combined with Varicella Zoster Vaccine (Live/attenuated).
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Monopotassium phosphate
The serum concentration of Choline salicylate can be increased when it is combined with Monopotassium phosphate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The risk or severity of adverse effects can be increased when Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)
The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)
The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Choline salicylate.
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen
The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Choline salicylate.